Literature DB >> 9343416

c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition.

J Bash1, W X Zong, C Gélinas.   

Abstract

A tetracycline-regulated system was used to characterize the effects of c-Rel on cell proliferation. The expression of c-Rel in HeLa cells led to growth arrest at the G1/S-phase transition, which correlated with its nuclear localization and the induction of endogenous IkappaB alpha expression. These changes were accompanied by a decrease in E2F DNA binding and the accumulation of the hypophosphorylated form of Rb. In vitro kinase assays showed a reduction in Cdk2 kinase activity that correlated with elevated levels of p21WAF1 Cdk inhibitor and p53 tumor suppressor protein. While the steady-state levels of WAF1 transcripts were increased, pulse-chase analysis revealed a sharp increase in p53 protein stability. Importantly, the deletion of the C-terminal transactivation domains of c-Rel abolished these effects. Together, these studies demonstrate that c-Rel can affect cell cycle control and suggest the involvement of the p21WAF1 and p53 cell cycle regulators.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343416      PMCID: PMC232506          DOI: 10.1128/MCB.17.11.6526

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  92 in total

Review 1.  p53: puzzle and paradigm.

Authors:  L J Ko; C Prives
Journal:  Genes Dev       Date:  1996-05-01       Impact factor: 11.361

2.  Avian I kappa B alpha is transcriptionally induced by c-Rel and v-Rel with different kinetics.

Authors:  J D Schatzle; J Kralova; H R Bose
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 3.  Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive & negative modulators.

Authors:  B Hoffman; D A Liebermann
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

Review 4.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation.

Authors:  H C Liou; W C Sha; M L Scott; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

6.  Induction of WAF1/CIP1 by a p53-independent pathway.

Authors:  P Michieli; M Chedid; D Lin; J H Pierce; W E Mercer; D Givol
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

7.  Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene.

Authors:  E S Hwang; L K Naeger; D DiMaio
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

8.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

9.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

Review 10.  Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways.

Authors:  D A Liebermann; B Hoffman; R A Steinman
Journal:  Oncogene       Date:  1995-07-06       Impact factor: 9.867

View more
  29 in total

Review 1.  New insights into the role of nuclear factor-kappaB in cell growth regulation.

Authors:  F Chen; V Castranova; X Shi
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

2.  Involvement of nuclear factor-kappaB in endothelin-A-receptor-induced proliferation and inhibition of apoptosis.

Authors:  M Mangelus; R Galron; Z Naor; M Sokolovsky
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 3.  NF-kappaB/Rel transcriptional pathway: implications in pancreatic cancer.

Authors:  Hana Algül; Guido Adler; Roland M Schmid
Journal:  Int J Gastrointest Cancer       Date:  2002

4.  Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1.

Authors:  Marianna Penzo; Paul E Massa; Eleonora Olivotto; Francesca Bianchi; Rosa Maria Borzi; Adedayo Hanidu; Xiang Li; Jun Li; Kenneth B Marcu
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

5.  IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes.

Authors:  K N Pennington; J A Taylor; G D Bren; C V Paya
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

6.  p65 Negatively regulates transcription of the cyclin E gene.

Authors:  Vaibhao C Janbandhu; Anup K Singh; Atish Mukherji; Vijay Kumar
Journal:  J Biol Chem       Date:  2010-04-11       Impact factor: 5.157

7.  The c-Rel Transcription Factor in Development and Disease.

Authors:  Thomas D Gilmore; Steve Gerondakis
Journal:  Genes Cancer       Date:  2011-07

8.  A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.

Authors:  Michael R Garbati; Ryan C Thompson; Leila Haery; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2011-01-12       Impact factor: 8.679

Review 9.  A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine.

Authors:  C Ansah; K B Mensah
Journal:  Ghana Med J       Date:  2013-09

10.  Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.

Authors:  Michael R Garbati; Gökçen Alço; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2009-11-30       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.